The mixed clinical results (IBD monotherapies positive, rheumatic disease programs discontinued) combined with the recent $350M offering create a binary event profile. Key catalysts are the SKYLINE Part B combination data in Q3 2027 and SKYLIGHT HS data in late 2027/early 2028. The activist stake (Fairmount at 9.19%) adds pressure for pipeline execution.
Drugs in focus
SYRE drug pipeline →SPY002
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- SPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.
- Next catalyst
- None dated
What to watchThe next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.
Price Chart
Executive Summary
Spyre Therapeutics reported Q3 2026 results with a net loss of $96.1M, wider than the $11.2M loss in Q3 2025, driven by higher R&D spending. The company announced positive Phase 2 data for all three IBD monotherapies (SPY001, SPY002, SPY003) but SPY072 failed primary endpoints in PsA and axSpA and will not advance in rheumatic disease. Pro forma cash stands at $1.47B after a $350M October offering, funding operations into 2H 2029.
Key Financial Metrics
Key Facts
- Net loss of $96.1M for Q3 2026 vs $11.2M in Q3 2025
- Pro forma cash of $1.47B as of September 30, 2026, including $378M net from October offering and $18M ATM sales
- SPY003 completed proof-of-concept for all three IBD monotherapies; Part B combination data expected Q3 2027
- SPY072 failed primary endpoints in PsA and axSpA sub-studies; will not advance in rheumatic disease
- New SKYLIGHT Phase 2 trial in HS initiated; topline data expected late 2027 or early 2028
- R&D expenses $89.2M in Q3 2026 vs $45.2M in Q3 2025
- Net cash used in operating activities was $77.5M for Q3 2026
- Common shares outstanding increased to 89.95M from 78.19M at year-end 2025
Financial Impact
Net loss widened by $84.9M year-over-year; cash burn $77.5M in operating activities; $378M net proceeds from October offering
Risk Factors
- SPY072 failure in PsA/axSpA raises questions about TL1A mechanism breadth beyond IBD
- Cash burn rate accelerating ($77.5M operating cash flow in Q3 alone) despite $1.47B pro forma cash
- Dilution from October offering (4.1M shares at $85) and ongoing ATM sales
- All pipeline candidates are still in Phase 2; no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000132 |
| Document: syre-20261103.htm | 0001636282-26-000132 |
| Document: 0001636282-26-000132-index-headers.html | 0001636282-26-000132 |
| Document: 0001636282-26-000132-index.html | 0001636282-26-000132 |
| Document: 0001636282-26-000132.txt | 0001636282-26-000132 |
| 8-K Data (Synthetic) | 0001636282-26-000132 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 Viewing No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers